The Definitive Industry Forum for Cross-Fibrosis
Disease Insights

Accelerate the Development of Transformative, Disease-Modifying Antifibrotic Therapeutics

The landmark FDA approval of the first MASH therapeutic, the orphan drug designation for systemic sclerosis trials, and the rapid advancement of IPF treatments through clinical phases have ignited a transformative era in fibrosis research. As focus shifts to other fibrotic diseases such as fibrosing IBD, cardiac fibrosis, and kidney fibrosis, the 8th Antifibrotic Drug Development Summit emerges as the definitive forum for innovation.

Uniting key decision-makers over three days, this summit delves into the latest breakthroughs, from discovery and novel targets to preclinical models and early-stage clinical trials, offering unparalleled insights to accelerate antifibrotic therapy development.

2024 EVENT GUIDE

49013 - SEO (2)

Your 25 Expert Speakers Include...

Previously Attending Companies Include...

2560px-Boehringer_Ingelheim_Logo.svg
Genentech_Logo
Pfizer_(2021)
Gilead_Logo
morphic-brand-notmlogo-rgb-082321-01

Your 2024 Partners Include:

FibroFind
images
Biomodels
NOVALIX, 8th Antifibrotic Drug Development Summit 2024

Other Events In the Series: